APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire)
NCT ID: NCT00523315
Last Updated: 2011-05-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
862 participants
OBSERVATIONAL
2007-05-31
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment
NCT00737009
Patient's Anastrozole Compliance to Therapy Programme
NCT00555867
Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer
NCT00437359
The Performance of Patient Support Program in Early Stage Breast Cancer
NCT00769080
Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer
NCT00022516
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with early breast cancer who are scheduled to receive first-line adjuvant endocrine therapy with aromatase inhibitor under the routine clinical practice
* Histologically or cytologically proven to be HR+(ER or PR +)
* Postmenopausal woman, defined as a woman fulfilling any of the following criteria(by the local guideline):
* Age \>= 50 years
* Age \< 50 years with amenorrhoea \> 12 months and an intact uterus
* FSH levels within postmenopausal range (over 30-40 IU/ml), or
* Having undergone a bilateral oophorectomy.
* No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators
Exclusion Criteria
* Known hypersensitivity to aromatase inhibitor or to any of the excipients
* Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the trial protocol
* Previous inclusion in the present study
* Participation in a clinical study during the last 30 days
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joon Woo Bahn
Role: STUDY_DIRECTOR
AstraZeneca Korea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Cheonan-si, Chuncheongnam-do, South Korea
Research Site
Kangnung-si, Gangwon-do, South Korea
Research Site
Bucheon-si, Gyeonggi-do, South Korea
Research Site
Goyang-si, Gyeonggi-do, South Korea
Research Site
Jinju, Gyeongsangnam-do, South Korea
Research Site
Anyang-si, Gyunggi-do, South Korea
Reserach Site
Euijungbu-si, Gyunggi-do, South Korea
Research Site
Seongnam, Gyunggi-do, South Korea
Research Site
Suwon, Gyunggi-do, South Korea
Research Site
Iksan-si, Jeollabuk-do, South Korea
Research Site
Jeonju, Jeollabuk-do, South Korea
Research Site
Busan, , South Korea
Research Site
Daegu, , South Korea
Research Site
Daejeon, , South Korea
Research Site
Daejoen, , South Korea
Research Site
Gwangju, , South Korea
Research Site
Incheon, , South Korea
Research Site
Seoul, , South Korea
Research Site
Ulsan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-OKR-ARI-2007/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.